Nervgen Pharma Corp (NGEN.VN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX Venture]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX Venture]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 06-2023 | 03-2023 | 12-2022 | 09-2022 | 06-2022 | |
| Cash Flows From Operating Activities | |||||
| Depreciation Amortization | 35 | 35 | 35 | 35 | 34 |
| Accounts receivable | 50 | -63 | -1 | 70 | -27 |
| Other Working Capital | 419 | -1,012 | 1,028 | -566 | 1,717 |
| Other Operating Activity | -2,503 | -3,741 | -6,116 | -4,348 | -5,418 |
| Operating Cash Flow | $-1,999 | $-4,782 | $-5,054 | $-4,809 | $-3,694 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -3 | 3 | 0 | -6 | -10 |
| Investing Cash Flow | $-3 | $3 | $0 | $-6 | $-10 |
| Cash Flows From Financing Activities | |||||
| Debt Repayment | -25 | -25 | -25 | -25 | N/A |
| Common Stock Issued | N/A | N/A | -21 | 19,784 | N/A |
| Other Financing Activity | 279 | 391 | 126 | 113 | 2,563 |
| Financing Cash Flow | $254 | $365 | $80 | $19,871 | $2,563 |
| Exchange Rate Effect | -191 | -16 | -274 | 994 | -37 |
| Beginning Cash Position | 18,021 | 22,452 | 27,700 | 11,650 | 12,828 |
| End Cash Position | 16,083 | 18,021 | 22,452 | 27,700 | 11,650 |
| Net Cash Flow | $-1,748 | $-4,414 | $-4,974 | $15,056 | $-1,142 |
| Free Cash Flow | |||||
| Operating Cash Flow | -1,999 | -4,782 | -5,054 | -4,809 | -3,694 |
| Capital Expenditure | N/A | N/A | N/A | -6 | -10 |
| Free Cash Flow | -1,999 | -4,782 | -5,054 | -4,814 | -3,704 |